
Oncology NEWS International
- Oncology NEWS International Vol 18 No 9
- Volume 18
- Issue 9
Avastin wins FDA OK for advanced kidney cancer treatment
Avastin (bevacizumab) plus interferon-alfa has been approved for the treatment of metastatic renal cell carcinoma, according to Genentech. Approval was based on phase III data from the AVOREN study, which showed a 67% increase in progression-free survival (10.2 months) compared to those who received interferon-alfa alone (5.4 months; hazard ratio = 0.60).
Avastin (bevacizumab) plus interferon-alfa has been approved for the treatment of metastatic renal cell carcinoma, according to Genentech. Approval was based on phase III data from the AVOREN study, which showed a 67% increase in progression-free survival (10.2 months) compared to those who received interferon-alfa alone (5.4 months; hazard ratio = 0.60).
Articles in this issue
over 16 years ago
Industry Watchover 16 years ago
Letter to the Editorover 16 years ago
Novel chemoRT regimen ups survival in pancreatic caover 16 years ago
Low expression of MSH2 protein predicts survival in NSCLCover 16 years ago
Prostate cancer pilot program stresses patient-oriented careover 16 years ago
CT distinguishes liver cancer mets from lung primaryover 16 years ago
Prostate cancer patients seek out mind-body careover 16 years ago
Who's NewsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


































